^（125）I－抗AFP放射免疫治疗原发性肝癌临床观察  

CLINICAL IBSERVATION OF ^(125)I-LABELED AN-TI-ALPHA FETOPROTEIN ANTIBODY RAOIOI-MMUNOTHERAPY IN HEPATOCkLLULAR CARCINOMA

作　　者：吴英德[1] 杨克政[1] 周德南[1] 甘友全[1] 宋向群[1] 胡晓桦[1] 黄秉琰[1] 

机构地区：[1]广西医科大学附属肿瘤医院,广西肿瘤防治研究所

出　　处：《广西医科大学学报》1996年第1期15-19,共5页Journal of Guangxi Medical University

基　　金：广西科委

摘　　要：将纯化抗ＡＦＰ多抗，用氯胺Ｔ氧化法标记￣（１２５）Ｉ，得￣（１２５）Ｉ－抗ＡＦＰ抗体进行导向治疗不能切除的肝癌２２例。均经静脉滴注。全组￣（１２５）Ｉ中位剂量为２８９．３（１００．３～７０８．９）ＭＢｑ，抗ＡＦＰ抗体的ＩｇＧ量为５．２ｍｇ（１．８～１２．８ｍｇ）。可评价疗效１９例，有效率为３１．６％（ＣＲ５．３％，ＰＲ２６．３％），总有效率（ＣＲ＋ＰＲ＋ＭＲ）为４２．１％，肿瘤缩小率为６３．２％（１２／１９）、ＡＦＰ下降率６４．７％（１１／１７），６例转阴，治后１年生存率为４７．１％（８／１７），７例尚存活，５例存括１４～３３个月。治疗耐受良好，毒副反应轻微。￣（１２５）Ｉ半衰期长，射线穿透力短，对正常组织扰乱少，使用方便，防护较简便，具有显著实用价值。patients with unresectable hepatocellular carcinoma(HCC)were treatedintravenously with 125I-anti AFP antibody,the median radioactive dose of which was289.3(100.3～708.9)MBq .Of these 22 cases the therapeutic response rate could be evaluated in19 cases.Their overall response rate was 31.6%(CR5.3%, PR26.3%),which was higher thanthe control group A(131 I-anti-AFP 4.0%,1/25,iv),control group B(anticancer drug-anti AFPconjugates,4.8%,1/21)and control group C(chemotherapy,8.0%,2/25).The serum AFP Ieveldecreased in 64.7% of the patients,and their tumor shrinkage rate was 63.2%,Their 1-yearsurivival rate(47.1%)was significantly higher than the control group A(16.0%),control group8(9.5%)control group C(8.0%).(P<0.05).Follow up observation showed that 7 of the 22 pa- tients with HCC were still alive after 10～33 months.This study indicates that 125I-anti-AFPcan be well tolerated,and side effects,if any,are minimal.125I possesses a long half-life of 60.2days and a low energy level of 28 KeV,It is a much safer radionuclide as compared with131I.Our result suggests that 125I-anti-AFP is a much more effective agent for treatingHCO.

关 键 词：原发性 肝肿瘤 碘125 甲胎蛋白 免疫疗法 

分 类 号：R735.705[医药卫生—肿瘤]